This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Meet Krishna, a 51-year-old AS patient1 with heel enthesitis.2
'It's been pretty tough since the divorce, especially because I'm now running the business on my own.'
'I've had heel pain for a long time2 but I guess I didn't realise how much having help took pressure off me.'
'Now I'm feeling stuck as my current treatment isn't relieving the pain. I've already tried NSAIDs, corticosteroid injections and sulfasalazine.1 I'm running out of hope and options.'
Enthesitis is present in >75% of patients with AS.3,* Heel enthesitis is often chronic and resistant to standard treatments.2
Note: This is a hypothetical case for representation purpose only.
AS patients with heel enthesitis such as Krishna benefit from treatment with Enbrel®2,4
Significant and clinically relevant improvement in refractory heel enthesitis2,†
Significantly greater improvements versus placebo in2,†:
- Heel pain
- Lower-limb function
- Patient-reported symptoms
Enbrel is well tolerated across all its indications1,5-28
axSpA: Predictable and manageable safety profile1,5,6
From HEEL, the first randomised, double-blind, placebo-controlled trial of a TNFi in 24 patients with refractory heel enthesitis in SpA.2,†
PGA of HEEL Enthesopathy Activity: Change From Baseline2
Example
Adapted from Dougados M, et al. 2010.
Other Measures: Change From Baseline to Week 122
Adapted from Dougados M, et al. 2010.
Significantly greater improvements in heel pain at Week 8 with Enbrel® versus placebo: −36.1 ± 24.0 versus −10.5 ± 24.0, respectively (P = 0.013)2
No significant between-group differences in MRI findings2
Please consult the LPD for contraindications, warnings, precautions and other important safety information.
Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which Enbrel® (etanercept) could be considered.
*From a cross-sectional study (N=118) that evaluated the frequency and severity of enthesitis in SpA and also assessed the correlation of enthesitis with clinical, laboratory and QoL parameters.3
†From HEEL, a 12-week, randomised, double-blind, placebo-controlled study that compared Enbrel® 50 mg QW versus placebo in 24 patients with SpA and refractory, MRI-positive heel enthesitis. Mean (±SD) normalised net incremental AUC for PGA of disease activity over 12 weeks was significantly greater with Enbrel® versus placebo: −28.5 ± 18.0 versus −11.1 ± 18.0, respectively; P = 0.029.2
Study design: The primary efficacy endpoint of HEEL was the normalised net incremental AUC between randomisation and Week 12 for PGA of heel enthesopathy activity (measured on a 100-mm VAS). Other endpoints included change from baseline in PGA of heel enthesopathy activity, heel pain (measured on a 100-mm VAS), WOMAC function subscale chosen as a measure of physical function in the lower limbs (0-100 normalised score, with 100 representing greatest functional impairment) and 2 endpoints evaluated by the patient: the patient-reported MCII (which defines whether observed difference [less pain] from baseline constitutes a trivial or an important improvement according to the patient) and the PASS. Efficacy was also assessed by the response at Week 12, defined as ≥50% improvement (decrease) from baseline in the PGA, and improvement in enthesitis as measured by MRI. Safety and tolerability were evaluated by assessing the incidence and severity of AEs.2
AS, ankylosing spondylitis; AUC, area under the curve; axSpA, axial spondyloarthritis; HEEL, A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial; MCII, minimum clinically important improvement; MRI, magnetic resonance imaging; NSAID, non-steroidal anti-inflammatory drug; PASS, patient acceptable symptom state; PGA, patient global assessment; QW, once a week; SD, standard deviation; SEM, standard error of the mean; SmPC, summary of product characteristics; SpA, spondyloarthritis; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities Arthritis Index.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ENB-IND-0814 August 2022
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.